Results 71 to 80 of about 19,734 (192)
Gastroenterology Insights, 2023 Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of
Ahlam Ayyad, Rami A. Al-Horani
doaj +1 more source
The Use of Non‐Selective Beta‐Blockers in Cirrhotic Portal Hypertension
Portal Hypertension &Cirrhosis, EarlyView.Non‐selective beta‐blockers (NSBBs) reduce portal pressure and play a key role in preventing variceal bleeding, managing ascites, and preventing hepatocellular carcinoma (HCC) in cirrhotic patients. Their clinical application requires individualized strategies and further optimization of indications. ABSTRACT Liver cirrhosis is the end stage of various
Tong Bu, Tianyuan Yang, Qi Wang
wiley +1 more source
Orthotopic liver transplantation for fulminant and subacute hepatic failure [PDF]
, 1988 Fulminant and subacute hepatitis are conditions characterized by rapid liver failure, which can lead to death in 80 to more than 95% of the cases with medical supportive care only.
Iwatsuki, S, Starzl, TE, Stieber, AC
core
Artificial Organs, EarlyView.The therapy with PAP using BR‐350 resulted in a significant decrease of bilirubin concentrations. The median relative reduction of bilirubin was comparable between PAP and OPAL (47% vs. 40%, p = 0.29). The crossover comparison between the single session of PAP using BR‐350 and OPAL revealed similar relative reduction rates of bilirubin.
Justa Friebus‐Kardash +8 more
wiley +1 more source
Features of the course of hepatorenal syndrome in decompensated portal hypertension (case report)
GastroenterologìaHepatorenal syndrome is a critical and potentially life-threatening complication in patients with advanced liver cirrhosis, characterized by the development of renal dysfunction in the absence of underlying structural kidney disease.
M.I. Tutchenko +4 more
doaj +1 more source
CLINICAL EFFICACY OF ALBUMIN DIALYSIS THERAPY FOR PATIENTS WITH HEPATORENAL SYNDROME
Вестник трансплантологии и искусственных органов, 2009 34 patients (23 male, 11 female) in the age of 41–77 years (mean age 59,7 ± 4,2 years) with 2 type hepatorenal syndrome were included in the study. All patients were divided in 3 groups.
D. E. Kutepov +8 more
doaj +1 more source
Role of human albumin in the management of liver cirrhosis
Медицинский совет, 2020 Aim. To demonstrate the role of concentrated human albumin in cirrhotic patient management.The main content. Albumin has a clear place in the clinical practice of cirrhotic patients managing.
M. V. Maevskaya, M. S. Zharkova
doaj +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.Extracellular matrix (ECM) remodelling biomarkers reflect portal hypertension and disease severity in advanced chronic liver disease (ACLD). However, their predictive value for disease progression is largely restricted to compensated ACLD (cACLD). ABSTRACT Background Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is ...
Benedikt Simbrunner +17 more
wiley +1 more source
Combined Liver-Kidney Transplantation for Hepatorenal Syndrome
International Journal of Organ Transplantation Medicine, 2015 Among various complications of end-stage liver disease, hepatorenal syndrome has the highest mortality. Patients with both end-stage liver disease and end-stage renal disease are candidates for combined liver-kidney transplantation.
V Kanubhai Sutariya +2 more
doaj
Combination octreotide, midodrine, and albumin may improve survival in patients with Hepatorenal syndrome, but the evidence is weak [PDF]
, 2017 A critical appraisal and clinical application of Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol.
Szafranski, Jacob
core +2 more sources